Mylan Lab’s Generic Amifostine Receives Approval In US
NASHVILLE, Tenn., Aug. 23, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing Ethyol® (amifostine) for injection to U.S. wholesalers today. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.
Cumberland Pharmaceuticals Inc. ('Cumberland', NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc ('Clinigen', AIM: CLIN), the global pharmaceutical and services company, have signed an exclusive agreement to commercialize the oncology support drug, Ethyol® (amifostine), in the U.S. This is the first product Clinigen has licensed to Cumberland under the strategic alliance entered into late last year.